MedTrace Logo

Comparison of Quality of Recovery (QoR)-15 Scores Between Propofol and Remimazolam Anesthesia

NCT05016518 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2022-06-01

No results posted yet for this study

Summary

Remimazolam is a ultra-short-acting benzodiazepine that is rapidly metabolized in the body by tissue esterase and not accumulates in the body for long periods of infusion. In addition, similar to other benzodiazepines, it is possible to reverse the sedation and anesthetic effects through flumazenil. It has no injection pain and infusion syndrome compared with propofol. There is no study to investigate overall postoperative functional recovery via QoR-15 in patients receiving TIVA using remimazolam. The purpose of this study is to determine whether there is any difference in the quality of postoperative recovery between propofol-based and remimazolam-based total intravenous anesthesia in female patients undergoing thyroidectomy. The QoR-15 questionnaire score, pain, nausea/vomiting, and the frequency of complications are evaluated and compared between the two groups.

Conditions

  • Patients Undergoing Thyroid Surgery for Neoplasm

Interventions

DRUG

Arm I (Propofol group)

Propfol group will be started and maintained total intravenous anesthesia with propofol and remifentanil .

DRUG

Arm II (Remimazolam group)

Remimazolam group will be started and maintained total intravenous anesthesia with remimazolam and remifentanil.

Sponsors & Collaborators

  • Gangnam Severance Hospital

    lead OTHER

Principal Investigators

  • Young Song · GangnamSeverance Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-16
Primary Completion
2022-05-18
Completion
2022-05-20

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05016518 on ClinicalTrials.gov